ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 723

Incidence and Variability of Cardiovascular Risk Factors in Female Lupus Patients: A 3-Year Follow-up

Carolinne Monção1, Leticia Martins1, Marcela Penteado1, Rodrigo Reis2, Fabiana Miranda Moura dos Santos3, CRISTINA COSTA LANNA3, Antônio Luiz Ribeiro4 and Rosa Weiss Telles4, 1Hospital das Clinicas, Universidade Federal of Minas Gerais, Belo Horizonte, Brazil, 2Universidade Federal of Minas Gerais, Belo Horizonte, Brazil, 3Medical School, Universidade Federal of Minas Gerais, Brazil, Belo Horizonte, Brazil, 4Medical School, Universidade Federal of Minas Gerais, Belo Horizonte, Brazil

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Co-morbidities, coronary artery disease, risk assessment and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster I: Biomarkers and Outcomes

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: To evaluate the incidence and variability of traditional coronary artery disease (CAD) risk factors in a cohort of systemic lupus erythematosus (SLE) patients.

Methods: 174 women were included (T0) in this prospective study on SLE atherosclerosis. The following traditional CAD risk factors were analyzed: hypertension (blood pressure ≥140/90 mmHg or antihypertensive medication), diabetes mellitus (DM) (fasting glucose ≥ 126mg/dl on at least two occasions or use of oral hypoglycemic agents or insulin), dyslipidemia (total-cholesterol ≥200mg/dl or HDL <40mg/dl or LDL ≥130mg/dl or use of oral lipid-lowering agents), hypertriglyceridemia (triglycerides ≥150mg/dl), obesity (body mass index ≥30kg/m2), abdominal obesity (waist circumference ≥88cm), smoking, positive family history for coronary event. Metabolic syndrome (MetS), according to Third Report of the NCEP/ATP III criteria, and Framingham risk score (FRS) were computed. The cumulative incidence between T0 and T1 for all risk factors was investigated. The incidence rate (person-years) for hypertension, DM, dyslipidemia and hypertriglyceridemia, with a CI95%, were calculated based in the data collected from the medical records. The frequency of risk factor disappearance at T1 (including the absence of treatment in the definition of disappearance), among patients with the risk factor at T0, was also described.

Results: The mean (SD) age at T0 of 151 patients reevaluated after 39 (36.5-42.0) months (T1) was 37.8 (11.1) years old, 75.5% non-white. The cumulative incidence, the incidence rate and the disappearance of some risk factors for CAD are presented in Table 1. The cumulative incidence during follow up were zero for smoking, 3.8% for positive family history for premature CAD, 16.5% for obesity, 18.8% for MetS and 39.1% for abdominal obesity. Eleven (11.7%) of 143 patients with low FRS in T0 were classified in high risk category in T1. Considering the risk factors disappearance, 26.0% with MetS at T0, 16.7% with obesity and 6.3% with abdominal obesity presented without the risk factor at T1. Only 1 (12.5%) patient within the higher risk of coronary event in 10 years (FRS>10%) at T0 “reduced” the risk to <10% in T1.

Conclusion: The authors identified a significant increase in the incidence of CAD risk factors in lupus patients with a follow-up of approximately 3 years. Conditions such as hypertension, obesity and DM presented less fluctuation than dyslipidemia between T0 and T1, raising considerations about the importance of statins use in lupus patients over time.

Table 1. Coronary artery disease risk factors cumulative incidence, incidence rate and disappearance after 39 (37-42) months, in lupus patients

Risk factor

Cumulative incidence*

Incidence rate

1000 person-years

(CI 95%)

Disappearance of risk factor**

Hypertension

18/79 (22.8%)

72.1 (38.8-105.4)

6/72 (8.3%)

Diabetes mellitus

5/143 (3.5%)

10.4 (1.3-19.5)

0

Dyslipidemia

33/89 (37.1%)

133.2 (87.8-178.6)

27/62 (43.5%)

LDL-c>130mg/dl

20/126 (15.9%)

49.9 (28.1-71.8)

9/25 (36.0%)

Total Chol>200mg/dl

27/122 (22.1%)

71.9 (44.8-99.0)

11/29 (37.9%)

HDL-c<40mg/dl

15/111 (13.5%)

44.2 (21.8-66.5)

27/40 (43.5%)

TGL>150mg/dl

16/108 (14.8%)

49.1 (25.0-73.1)

18/30 (41.9%)

*Incident case/Number of patients without risk factor at T0.

**Number of patients with disappearance of a risk factor/Number of patients with the risk factor at T0.


Disclosure: C. Monção, None; L. Martins, None; M. Penteado, None; R. Reis, None; F. M. M. dos Santos, None; C. C. LANNA, None; A. L. Ribeiro, None; R. W. Telles, None.

To cite this abstract in AMA style:

Monção C, Martins L, Penteado M, Reis R, dos Santos FMM, LANNA CC, Ribeiro AL, Telles RW. Incidence and Variability of Cardiovascular Risk Factors in Female Lupus Patients: A 3-Year Follow-up [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/incidence-and-variability-of-cardiovascular-risk-factors-in-female-lupus-patients-a-3-year-follow-up/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/incidence-and-variability-of-cardiovascular-risk-factors-in-female-lupus-patients-a-3-year-follow-up/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology